38 related articles for article (PubMed ID: 16956760)
1. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
Salmon BA; Salmon HW; Siemann DW
Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
[TBL] [Abstract][Full Text] [Related]
2. Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials.
Virumbrales-Muñoz M; Chen J; Ayuso J; Lee M; Abel EJ; Beebe DJ
Lab Chip; 2020 Nov; 20(23):4420-4432. PubMed ID: 33103699
[TBL] [Abstract][Full Text] [Related]
3. MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting.
Burrell JS; Bradley RS; Walker-Samuel S; Jamin Y; Baker LC; Boult JK; Withers PJ; Halliday J; Waterton JC; Robinson SP
Microvasc Res; 2012 Nov; 84(3):323-9. PubMed ID: 22921880
[TBL] [Abstract][Full Text] [Related]
4. Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.
Benezra M; Phillips E; Tilki D; Ding BS; Butler J; Dobrenkov K; Siim B; Chaplin D; Rafii S; Rabbany S; Bradbury MS
Leukemia; 2012 Aug; 26(8):1771-8. PubMed ID: 22343591
[TBL] [Abstract][Full Text] [Related]
5. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography.
Folarin AA; Konerding MA; Timonen J; Nagl S; Pedley RB
Microvasc Res; 2010 Jul; 80(1):89-98. PubMed ID: 20303995
[TBL] [Abstract][Full Text] [Related]
7. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503.
Wankhede M; Dedeugd C; Siemann DW; Sorg BS
Oncol Rep; 2010 Mar; 23(3):685-92. PubMed ID: 20127007
[TBL] [Abstract][Full Text] [Related]
8. An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.
Pettit GR; Minardi MD; Hogan F; Price PM
J Nat Prod; 2010 Mar; 73(3):399-403. PubMed ID: 20028026
[TBL] [Abstract][Full Text] [Related]
9. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
11. New vascular disrupting agents in upper gastrointestinal malignancies.
Quatrale AE; Porcelli L; Gnoni A; Numico G; Paradiso A; Azzariti A
Curr Med Chem; 2014; 21(8):1039-49. PubMed ID: 23992324
[TBL] [Abstract][Full Text] [Related]
12. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
Salmon HW; Mladinich C; Siemann DW
Eur J Cancer; 2006 Nov; 42(17):3073-8. PubMed ID: 16956760
[TBL] [Abstract][Full Text] [Related]
13. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Siemann DW; Shi W
Anticancer Res; 2008; 28(4B):2027-31. PubMed ID: 18751370
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Dalal S; Burchill SA
Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
